Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-15. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
The International Space Station is fitted with rehydration chambers and food warmers to prepare the packaged food before consumption. The first galley on ISS was located in the Russian Orbital Segment (ROS), containing a hydration system for reheating food, and a food warmer for canned food. The United States developed the second food warmer system in a briefcase-like shape to provide the reheating function for packet-style food items. A second galley was added to the Unity module due to the crew size increase. Combined dinners were rare, as Russian, Space Shuttle, and other ISS astronauts were often eating in their own segments with different schedules. On Tiangong Space Station, the kitchen is located in the Tianhe core module, along with living quarters and entertainment systems. The kitchen is equipped with a small table for food preparation and the first-ever microwave oven in spaceflight. Huang Weifen, the chief astronaut trainer of China Manned Space Agency (CMSA), explained that the intention was to make sure that astronauts can "always have hot food whenever they need." China later experimented with using convection oven in space. Shenzhou 21 delivered an air fryer to the Tiangong, which features built-in air purification and residue collector to allow safe usage inside confined space and microgravity. The new oven allows baking and grilling of food, instead of simple reheating. Chinese astronauts cooked barbecue chicken wings and grilled steak with it.
==== Mineral extraction and hardware footprint ==== The physical infrastructure of AI, specifically the Graphics Processing Units (GPUs) and data centres required to train and run large language models, relies heavily on critical minerals and rare earth elements. A 2026 study published in Nature Communications Earth & Environment quantified the material footprint of AI training, revealing that AI hardware consists of approximately 90% heavy metals. The study estimated that training a single large language model requires the equivalent lifetime consumption of between 1,760 and 8,800 GPUs, underscoring that incremental model performance gains come at disproportionately high material costs. The extraction of these minerals, such as cobalt, lithium, tantalum, and coltan, is heavily concentrated in the Global South and is frequently associated with severe environmental degradation and human rights abuses. For example, the Democratic Republic of Congo (DRC) holds roughly 70% of the world's cobalt reserves, alongside vast deposits of coltan and copper. Academic analyses note that the global AI supply chain relies on a familiar geopolitical division of labour: African countries mine the raw materials, while Western and East Asian economies refine them and capture the technological value. In the UK, a coalition of NGOs including Friends of the Earth, the Trade Justice Movement, and the London Mining Network published a joint report in May 2026 criticising the UK Government's critical minerals agenda.
==== Epidermal receptor (Sense organ) ==== Epidermal receptors are abundant and distributed all over the epidermis. Each receptor shows a slightly elevated cuticle which covers a group of tall, slender and columnar receptor cells. These cells bear small hairlike processes at their outer ends and their inner ends are connected with nerve fibres. The epidermal receptors are tactile in function (mechanoreceptor) and can respond to touch, cuticle deformation, gravity and sound. They also respond to chemical stimuli (chemoreceptors). Earthworms are extremely sensitive to mechanical vibrations (e.g. trampling, earthquakes) which make them emerge from the soil and crawl at its surface, a reflex used by earthworm harvesters (e.g. fishers) to catch them easily.
An initial tree, Ti, is randomly selected. A neighbour tree, Tj, is selected from the collection of trees. The ratio, R, of the probabilities (or probability density functions) of Tj and Ti is computed as follows: R = f(Tj)/f(Ti) If R ≥ 1, Tj is accepted as the current tree. If R < 1, Tj is accepted as the current tree with probability R, otherwise Ti is kept. At this point the process is repeated from Step 2 N times. The algorithm keeps running until it reaches an equilibrium distribution. It also assumes that the probability of proposing a new tree Tj when we are at the old tree state Ti, is the same probability of proposing Ti when we are at Tj. When this is not the case Hastings corrections are applied. The aim of Metropolis-Hastings algorithm is to produce a collection of states with a determined distribution until the Markov process reaches a stationary distribution. The algorithm has two components:
Sources: en.wikipedia.org
== Chemists == For more chemists, see: Nobel Prize in Chemistry and List of chemists Amedeo Avogadro Elias James Corey Marie Curie John Dalton Humphry Davy George Eastman Michael Faraday Rosalind Franklin Eleuthère Irénée du Pont Dmitriy Mendeleyev Alfred Nobel Wilhelm Ostwald Louis Pasteur Linus Pauling Joseph Priestley Robert Burns Woodward Karl Ziegler Ahmed Zewail
Wiley (1844–1930), American chemist, pure food and drug advocate Sir Geoffrey Wilkinson (1921–1996), English chemist, 1973 Nobel Prize in Chemistry Alexander William Williamson (1824–1904), English chemist, famous for Williamson ether synthesis Thomas Willson (1860–1915), Canadian chemist, discovered an economically efficient process for creating calcium carbide Richard Willstätter (1872–1942), German chemist, 1915 Nobel Prize in Chemistry Adolf Otto Reinhold Windaus (1876–1959), German chemist, 1928 Nobel Prize in Chemistry Günter Wirths (1911–2005), German chemist Georg Wittig (1897–1987), German chemist, 1979 Nobel Prize in Chemistry Friedrich Wöhler (1800–1882), German chemist, best known for his synthesis of urea William Hyde Wollaston (1766–1828), English chemist, discovered the elements palladium and rhodium Robert B. Woodward (1917–1979), American chemist, 1965 Nobel Prize in Chemistry Charles de Worms (1903–1979), English chemist and lepidopterist Charles-Adolphe Wurtz (1817–1884), Alsatian French chemist, discovered the Wurtz reaction Kurt Wüthrich (born 1938), 2002 Nobel Prize in Chemistry
Their global dissemination is driven in part by horizontal gene transfer on plasmids and has been associated with selection pressure from colistin use, particularly in food-producing animals. Mobile colistin resistance genes also occur in settings without local agricultural colistin use. A 2026 genomic study from New Zealand, where colistin has never been licensed for use in food-producing animals, characterized 71 mcr-positive clinical isolates and compared them with 1,543 mcr-carrying plasmids sampled from 60 countries and regions between 1984 and 2024. The analysis resolved 14 major plasmid lineages associated with different mcr variants and found frequent co-carriage of other antimicrobial-resistance genes, indicating that transmissible plasmid backbones and co-selection by other resistance determinants can contribute to the persistence and dissemination of mcr genes even where direct colistin selection pressure is limited. The emergence of the mcr-9 gene is quite remarkable. Use of colistin to treat Acinetobacter baumannii infections has led to the development of resistant bacterial strains. They have also developed resistance to the antimicrobial compounds LL-37 and lysozyme, produced by the human immune system. This cross-resistance is caused by gain-of-function mutations to the pmrB gene, which controls the expression of lipid A phosphoethanolamine transferases (similar to mcr-1) located on the bacterial chromosome. Similar results have been obtained with mcr-1 positive E.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.